Simultaneous Molecular Detection of Mycobacterium Tuberculosis and Multidrug Resistance

Table 1_Simultaneous molecular detection of Mycobacterium tuberculosis and multidrug resistance using CRISPR-AaCas12b-based nucleic acid assay.xlsx contains validation data for a diagnostic assay. The dataset, authored by Yujiao Hu and last updated on 2026-05-19, includes performance metrics from 48 clinical samples. It reports sensitivity, specificity, and limit of detection for detecting MTB and specific drug-resistance mutations.

Use Cases

• Benchmarking new diagnostic assays based on reported sensitivity and specificity metrics.
• Modeling the performance of CRISPR-Cas based detection systems for infectious diseases.
• Analyzing the correlation between molecular markers and phenotypic drug resistance in tuberculosis.

Strengths

• Performance metrics are reported with specific numbers, including a sensitivity of 97.1% for MTB detection.
• The assay's limit of detection is quantified as 1.5 CFU/mL.
• Validation was conducted against established reference standards like WHO-recommended GeneXpert and sequencing.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small at 27.4 KB, indicating limited scope.

Provenance

Source

Yujiao Hu via figshare

Collection Method

Data likely generated from validating a multiplex-RPA CRISPR-AaCas12b assay on 48 clinical samples.

Freshness

Last updated 2026-05-19 05:29:14; freshness should be verified.